- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, September 27, 2024
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
An article from Becker’s ASC Review referenced a study published in the April 2024 issue of The American Journal of Managed Care® (AJMC®). The study, “Prices and Complications in Hospital-Based and Freestanding Surgery Centers,” found that higher prices for procedures performed in hospital outpatient departments did not indicate better quality compared with procedures performed in nonhospital ambulatory surgery centers.
A report released by the National Association of ACOs cited 2 studies published in AJMC. The first, “Changes in Specialty Care Use and Leakage in Medicare Accountable Care Organizations,” was published in the May 2018 issue and found that leakage of specialty care changed minimally in the Medicare Shared Savings Program. The second, “Accountable Care Organization Initiatives to Improve the Cost and Outcomes of Specialty Care,” was released in the May 2024 issue and found that engaging specialists in accountable care has numerous challenges and represents an emerging area for accountable care organizations.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
